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Abstract
Background: In consideration of patients seeking to use traditional Chinese medicine, an evidence-based
potentiality for safe and effective use of herbal medicine and acupuncture in treatment of acne vulgaris has been
suggested. However, despite common use of a combination of herbal medicine and acupuncture in clinical
practice, the current level of evidence is insufficient to draw a conclusion for an interaction and efficacy of herbal
medicine and acupuncture. Therefore, considering these methodological flaws, this study was designed to assess
the interaction and efficacy of an available herbal medicine, Keigai-rengyo-to extract (KRTE), and acupuncture for
treatment of acne using the 2 × 2 factorial design and the feasibility of a large clinical trial.
Methods/Design: A randomized, assessor single blinded, 2 × 2 factorial pilot trial will be conducted. Forty four
participants with acne vulgaris will be randomized into one of four groups: waiting list group (WL), KRTE only
group (KO), acupuncture only group (AO), and KRTE and acupuncture combined treatment group (KA). After
randomization, a total of 8 sessions of acupuncture treatment will be performed twice a week in the AO- and KA
groups, respectively. Patients in the KO- and KA groups will be prescribed KRTE 3 times a day at a dose of 7.4 g
after meals for 4 weeks. The following outcome measurements will be used in examination of subjects: the mean
percentage change and the count change of inflammatory and non-inflammatory acne lesions, the Skindex 29,
visual analogue scale (VAS) and investigator global assessment (IGA) from baseline to the end of the trial.
Trial Registration: The trial is registered with the Clinical Research Information Service (CRiS), Republic of Korea:
KCT0000071.
Background
Acne vulgaris is a common skin disease encountered in
dermatology practice; it is caused by changes in pilose-
baceous units [1,2]. It is common in adolescence and
may proceed into adulthood, affecting roughly 33% of
people between the ages of 15 and 44 years [3], or
affecting nearly 80% of adolescents and young adults
aged 11 to 30 years [4].
Acne vulgaris is a chronic dermatosis of the pilosebac-
eous follicle with four fundamental etiopathogenic factors:
sebaceous hyperproduction, follicular hyperkeratinization,
increase of Propionibacterium acnes colonization, and
periglandular dermal inflammation [5]. Western medical
treatment options generally target one or more of the fac-
tors implicated in these acne pathogeneses [6] with topical
or systemic agents, phototherapy narrowband light (blue
or red), and acne vaccines [7-9].
Despite this treatment for care of acne vulgaris, a sub-
stantial number of acne patients widely seek to use tradi-
tional Chinese medicine (TCM) due to a lack of response
to western medical treatment [10] and their concern
regarding side effects, such as burning, erythema, desqua-
mation, pigmentation, xerosis, and chapped lips, among
others [11-15].
Herbal medicine and acupuncture are two of the
major tools of TCM therapy and have been frequently
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practice worldwide, particularly in East Asia [16]. In
South Korea, Japan, and China, the evidence-based
potentiality for safe and effective use of herbal medicine
and acupuncture in treatment of acne vulgaris has been
suggested [17-27]. However, the current level of evi-
dence is poor due to the small number of good quality
studies, small sample size, short duration, and variation
in the composition of herbal interventions or acupunc-
ture [28]. In addition, despite common use of a combi-
nation of herbal medicine and acupuncture in clinical
practice, these studies have rarely demonstrated an
interaction between herbal medicine and acupuncture,
and have rarely used a waiting list- or western medical
treatment group as a control group.
Considering these methodological flaws, we will con-
duct a trial to assess the interaction effect and efficacy
of Keigai-rengyo-to extract (KRTE) and acupuncture
using the 2 × 2 factorial design and the feasibility of a
large clinical trial. KRTE is an herbal medicine that is
often prescribed for treatment of acne; it is approved by
the Korea Food and Drug Administration. Females,
through the menstrual cycle, can be easily affected by
the level of sex hormones, such as estrogen and andro-
gen, relevant to increased sebum production, which play
a central role in development of acne; therefore, we will
restrict the participants to male patients with acne
vulgaris [2,29].
Method/Design
Objective
The aim of this study is to investigate the efficacy and
interaction of KRTE in male patients with acne vulgaris
and evaluate the feasibility of a large clinical trial.
The null hypothesis is as follows: (1) there is no inter-
action of KRTE and acupuncture treatment on mean
percent change of inflammatory acne lesions between
baseline and the end of the trial; (2) mean percent
change of inflammatory acne lesions between baseline
and the end of the trial is equal in both the KRTE treat-
ment group and the waiting list group; (3) mean percent
change of inflammatory acne lesions between baseline
and the end of the trial is equal in both the acupuncture
treatment group and the waiting list group.
Design
This study is a randomized, 2 × 2 factorial, waiting list
controlled, assessor single blinded and single-center
pilot trial.
The study will be sequentially conducted as follows:
enrollment after screening via inclusion and exclusion
criteria, randomization, a treatment period of 4 weeks,
and assessment (Figure 1).
Participants and Eligibility
Inclusion criteria
According to the Korean acne grading system [30],
patients are divided into 6 grades. Only grade 2 to 4
patients (with papules ≥ 10 or nodules ≤ 20, ± mild
ongoing scars), who have had acne for more than
3 months (chronic stage) between the ages of 13 to
35 years, are eligible to participate in this trial.
Exclusion criteria
The author will exclude patients outside the normal range
on blood tests, including aspartate transaminase (AST),
alanine transaminase (ALT), blood urea nitrogen (Bun),
creatinine, hemoglobin, and platelet (normal range: 13 ≤
hemoglobin ≤ 17 g/dl, 150000 ≤ platelet ≤ 350000/mm3,
aspartate transaminase (AST) < 40 IU/L, alanine transami-
nase (ALT) < 40 IU/L, 8 ≤blood urea nitrogen (BUN) 23
mg/dl and 0.6 ≤ creatinine ≤ 1.2 mg/dl). Participants are
ineligible if they have experienced western medical treat-
ment or traditional medical treatment for acne within
4 weeks prior to recruitment or have keloid acne, corticos-
teroid acne, infectious skin disease, or internal disease
requiring first aid. Participants will also be excluded if they
are not willing to not comply with this study protocol.
Within 4 weeks after enrollment in this trial, no concomi-
tant acne therapy will be permitted and patients will be
instructed to use non-comedogenic makeup or sunscreen.
Recruitment
Participants will be recruited via internet advertisement
posted on the website of the Kyung Hee Medical Center
and via ad-posters.
Randomization and blinding
After enrollment, participants will be randomly assigned
to the waiting list (WL), acupuncture only (AO), KRTE
only (KO), and KRTE combined with acupuncture treat-
ment (KA) groups. The allocation ratio will be 1:1:1:1 in
blocks of 4. Randomization will be performed at a site
remote from trial location. Random numbers will be gen-
erated by a computerized random-number generator
through the block-randomization method of a software
program (Excel, Microsoft Office 2007) for sequence gen-
eration and we will make two separate database: a
“patients” database that lists basic information such as
patient name, contact details and so on, and a “randomi-
zation” database that holds data on which patients have
been registered on trial along with their allocations. The
“patients” database will be accessible to any researcher
whereas the “randomization” database will be password
protected so that it will be accessible only by the princi-
pal investigator and a nominated statistician [31]. The
assessor, who will not be the acupuncture practitioner
and KRTE supplier, and who is blinded to the allocation
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assessment.
Intervention
KRTE
KRTE is approved by the Korea Food and Drug Admin-
istration as a prescription in clinical practice for patients
with sinusitis, otitis media, and acne. The components
of KRTE are presented in Table 1. The authors pur-
chased KRTE from the Han Kook Sin Yak Pharm. Co.,
which is equipped with a Korean good manufacturing
practice (KGMP) facility. Participants in the KO and KA
groups will be prescribed KRTE three times a day at a
dose of 7.4 g after meals for 4 weeks.
Acupuncture
Certified acupuncture practitioners who have a minimum
of 3 years of clinical experience obtained after a 6-year
oriental medical college course will perform the acupunc-
ture treatment. They will take a one-day training course
for this trial. This course will include the study protocol,
methods for acupuncture treatment, and basic informa-
tion on clinical research. Eight sessions of acupuncture
Figure 1 Flow chart of the study.
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weeks in patients who will be assigned to the AO and KA
groups. Patients will receive acupuncture treatment at 11
classical acupuncture points and/or ah shi points that
were randomly selected at papules and nodules on the
face by the acupuncture practitioner. The following 11
acupuncture points will receive bilateral treatment: ST2
(Sibai), ST6 (Jiache), ST36 (Zusanli), LI20 (Yingxiang),
LI11 (Quchi), PC6 (Neiguan), HT8 (Shaofu), SP3 (Tai-
bai), SP6 (Sanyinjiao), SP10 (Xuehai), and LR3 (Tai-
chong). These points will be treated with 0.25 × 30 mm
disposable acupuncture needles (Dongbang Co., Korea).
Selection of these acupuncture points was based on a lit-
erature review and previous studies of acupuncture treat-
ment of acne vulgaris [20,21] and from the attending
doctor’s clinical experience and they will be located
according to WHO standard Acupuncture Point Loca-
t i o n si nt h eW e s t e r nP a c i f i cR e g i o n[ 3 2 ] .P a t i e n t sw i l l
remain in a supine position for 15 minutes during acu-
puncture treatment. Papules and nodules will not be arti-
ficially extruded.
Waiting list group
Participants who will be assigned to the WL group will not
receive any acupuncture or KRTE treatment throughout
the 4-week post-randomization period. After the end of
the study, if participants elect to undergo acupuncture
treatment, it will be provided twice weekly for 4 weeks.
Outcome measures
Primary outcome
Primary outcome will be presented by the mean percen-
tage change of inflammatory lesion counts from baseline
to the end of the trial [29,33].
Secondary outcomes
Secondary outcomes will be shown by the mean percen-
tage change of non-inflammatory lesion counts from
baseline to the end of the trial, count of inflammatory
and non-inflammatory lesions, the quality-of-life scale
(Skindex-29), Visual Analogue Scale (VAS) [score 0 (no
symptoms) to 100 (severe symptoms)], and the Investi-
gator Global Assessment [IGA; after evaluation from
score 1 (very good) to 5 (very poor) every session, we
divided into ‘improvement’ or ‘non-improvement’
between baseline and the end of the study]. Skindex 29
will be checked at weeks 0 (baseline) and 4 (end of the
trial). VAS and IGA will be checked every session from
baseline (just before randomization) and through the
4 weeks after randomization. A Lumix DMC-LX2 digital
camera (Panasonic, Osaka, Japan) was used to photo-
graph each patient’s face, so that inflammatory and
non-inflammatory lesions could be counted at weeks 0
(baseline) and 4 (end of the trial).
Statistical methods
Statistical analysis plan
Statistical analysis will be conducted on an intension-to-
treat basis with a 95% confidence interval using SPSS
version 12.0 for Windows. Missing values of drop-out
participants will be imputed by the last observation car-
ried forward (LOCF) method. Data will be displayed as
the mean ± standard deviation (SD) for continuous data
or n (%) for categorical data.
Baseline data and Outcome data
A two-way analysis of covariance (ANCOVA) test will be
used to examine the percentage change of inflammatory
and non-inflammatory lesions from baseline to the end
of the trial when controlling for baseline and other cov-
ariates. A repeated measured ANCOVA test will be per-
formed for evaluation of any significant difference in
count of inflammatory and non-inflammatory lesions,
Skindex-29 score, and VAS score between baseline and
the end of the trial. If there is an interaction between
KRTE and acupuncture, only the interaction will be
shown. If not, the main effect of KRTE and acupuncture
will be reanalyzed and presented. According to ‘improve-
ment’ or ‘no-improvement’ of IGA score between
b a s ei n ea n dt h ee n do ft h et r i a l ,t h ed i f f e r e n c ea m o n g
the groups will be evaluated using a Chi-square test or
Fisher’s exact test.
Proportion of drop-outs and compliance with KRTE
and questionnaire completion will be calculated and
described as n (%). The percentage of subjects in each
group will be compared using a Chi-square test or Fish-
er’s exact test.
All adverse events reported during the study will be
included in the case report forms; the incidence of
adverse events will be calculated. The percentage of sub-
jects with adverse events in each group will be calcu-
lated and compared using a Chi-square test or Fisher’s
exact test.
Table 1 Components of KRTE (7.4 g/dose)
Scientific Name Amount (g)
Schizoneptae Herba 0.27
Forsythiae Fructus 0.34
Ledebouriellae Radix 0.65
Angelicae gigantis Radix 0.70
Cnidii Rhizoma 0.65
Paeoniae Radix 0.32
Bupleuri Radix 0.59
Aurantii Fructus 0.86
Scutellariae Radix 0.67
Gardeniae Fructus 0.89
Angelicae dahuricae Radix 0.35
Platycodi Radix 0.51
Glycyrrhizae Radix 0.67
Total 7.40
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KRTE remaining after each session will be quantified in
order to enhance medication compliance. Participants
whose compliance with KTRE is ≤ 80% of the total dose
or who receive fewer than six acupuncture sessions will
be considered to have dropped-out.
Adverse events and monitoring safety
All unexpected adverse events related to KRTE and acu-
puncture treatment will be reported to the investigator
or acupuncture practitioner by participants and written
on the individual case report form by the investigator.
Safety will be assessed by the reporting of clinical
laboratory tests, vital sign measurements, and adverse
events. Clinical laboratory tests, including AST/ALT,
BUN/creatinine, red blood cell (RBC) count, white
blood cell (WBC) count, hemoglobin, hematocrit, mean
cell volume (MCV), mean cell hemoglobin (MCH),
mean cell hemoglobin concentration (MCHC), number
of platelets, and number of differentiated cells will be
determined at weeks 0 (baseline) and 4 (end of the
trial). Vital signs of each participant will be checked
with monitoring of adverse events (pain on the acne
lesion or other sites, nausea/vomiting, fatigue, allergic
reaction, and any adverse events related to KRTE and
acupuncture) after each visit.
Sample size
This study is a pilot study for evaluation the interaction
and efficacy of KRTE and acupuncture in male patients
with acne vulgaris and the feasibility of a large clinical
trial. Because this trial was designed to be of short dura-
tion, lasting four weeks, with the intention of decreasing
the drop-out rate, the desired sample size for this pilot
study is 44 patients, with 11 for each group, assuming a
drop-out rate of 10%.
Ethics
The study protocol and the written informed consent
were approved by the institutional review board (IRB) of
the Oriental Medical Hospital at Kyung Hee Medical
Center (KOMC IRB 2009-06). Each participant will be
notified regarding the study protocol. Written informed
consent will be obtained from each patient.
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